10 October 2024
Kelso Group Holdings Plc
("Kelso" or the "Company")
Comment on THG Plc
Kelso, the main market listed acquisition vehicle, notes the announcement from THG Plc ('THG') at 4.52pm today regarding the early advancement of its plans to demerge Ingenuity and the associated placing. THG is Kelso's second largest shareholding.
Kelso believes in Ingenuity's model and its long term future and that the demerger will be highly beneficial for Ingenuity, as well as for THG Beauty and MyProtein as the remaining parts of THG. Kelso believes that the value of the two remaining businesses are each worth more than the current market capitalisation of THG.
Kelso is also supportive of the placing announced today and pleased with the board's speed of execution and decisive action. Kelso intends to participate in the placing.
For further information please contact:
| Kelso Group Holdings plc | +44 (0) 75 4033 3933 |
| John Goold, Chief Executive Officer Mark Kirkland, Chief Financial Officer Jamie Brooke, Chief Investment Officer | |
| Zeus (Broker) | +44 (0) 20 3829 5000 |
| Nick Cowles, Ed Beddows, John Moran (Investment Banking) Ben Robertson (Corporate Broking) | |
| Camarco | +44 (0) 20 3757 4980 |
| Billy Clegg, Tom Huddart | |
About Kelso
Kelso was established in November 2022 to identify, engage and unlock trapped value in the UK stock market. Kelso's strategy is to invest in situations where it believes there is an anomaly between the intrinsic value and prospects of a company and its stock market valuation. Kelso will, in particular, look for situations where it believes the sum of the parts of a business is greater than the current value. The Kelso team is led by an experienced and well-invested Board and management team with a track record of identifying and creating value in the UK small and mid-cap public markets. There may be instances where Kelso itself could be used as a vehicle by an undervalued company to spin off a subsidiary into its own listing. The board of Kelso owns 20.5% of the equity having invested in each of the last three fundraising rounds.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
